TTY Biopharm Company Limited (TPEX:4105)

Market Cap	18.55B -6.8%
Revenue (ttm)	6.45B +9.5%
Net Income	1.56B +7.6%
EPS	6.26 +7.6%
Shares Out	248.65M
PE Ratio	11.92
Forward PE	10.91
Dividend	4.50 (6.03%)
Ex-Dividend Date	Mar 26, 2026

Volume	550,684
Average Volume	1,078,026
Open	74.70
Previous Close	74.60
Day's Range	73.60 - 74.80
52-Week Range	72.40 - 87.00
Beta	0.17
RSI	36.10
Earnings Date	Mar 27, 2026

About TTY Biopharm Company

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers oncology drugs for the treatment of anticancer and adjunctive therapies under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1960
• Employees: 342
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4105

Financial Performance

In 2025, TTY Biopharm Company's revenue was 6.45 billion, an increase of 9.49% compared to the previous year's 5.89 billion. Earnings were 1.56 billion, an increase of 7.55%.